Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bellicum Pharma Comm (NQ: BLCM )

4.470 USD -0.390 (-8.02%)
Official Closing Price Updated: 7:58 PM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Bellicum Pharma Comm

< Previous 1 2 3 4 5 6 7 Next >
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
From ACCESSWIRE
Bellicum Pharmaceuticals Appoints Edmund P. Harrigan, M.D. to its Board of Directors
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of... 
From GlobeNewswire News Releases
IMPORTANT INVESTOR REMINDER FOR ALL OWNERS OF BELLICUM PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the U
Lead Plaintiff Deadline is April 9, 2018 
From GlobeNewswire News Releases
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of... 
From Business Wire News Releases
NASDAQ:BLCM Shareholder Alert: Lawsuit Alleges Misleading Statements by Bellicum Pharmaceuticals Inc
San Diego, CA -- (SBWIRE) -- 02/20/2018 -- An investor, who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), filed a lawsuit in over alleged Securities Laws violations by Bellicum... 
From SBWire - Latest Press Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM) and certain of its officers. The class action,... 
From PR Newswire
BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCM
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) from May 8, 2017 through January 30, 2018, inclusive (the “Class... 
From Business Wire News Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
From ACCESSWIRE
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm
From ACCESSWIRE
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM
From ACCESSWIRE
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline – April 9, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:... 
From GlobeNewswire News Releases
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern District of Texas against Bellicum Pharmaceuticals, Inc.... 
From GlobeNewswire News Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers - BLCM
From ACCESSWIRE
Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action
Do you own shares of Bellicum Pharmaceuticals, Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Bellicum. 
From Business Wire News Releases
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) T
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of... 
From GlobeNewswire News Releases
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bellicum Pharmaceuticals, Inc. (BLCM)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) in the United States District Court for... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bellicum Pharmaceuticals, Inc. (BLCM) & Lead Plaintiff Deadline - April 9, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ:... 
From PR Newswire
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bellicum Pharmaceuticals, Inc.
From ACCESSWIRE
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) from May 8,... 
From Business Wire News Releases
BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM). 
From PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM
Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc. (“Bellicum” or the “Company”) (NASDAQ:BLCM) and certain of its officers. The class action,... 
From GlobeNewswire News Releases
Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellicum Pharmaceuticals, Inc. (BLCM)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM). Such... 
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bellicum Pharmaceuticals, Inc. - BLCM
Pomerantz LLP is investigating claims on behalf of investors of Bellicum Pharmaceuticals, Inc. ("Bellicum" or the "Company") (NASDAQ: BLCM). Such investors are advised to contact Robert S. Willoughby... 
From PR Newswire
Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has... 
From GlobeNewswire News Releases
This Morning's Technical Outlook on Biotech Stocks -- Moleculin Biotech, Vanda Pharma, Iovance Biotherapeutics, and Bellicum Pharma
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MBRX, VNDA, IOVA, and BLCM which can be accessed for free by signing up to... 
From PR Newswire
Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting
Results support technology’s potential to control activation, persistence, and elimination of cell therapies for improved safety and efficacy 
From GlobeNewswire News Releases
Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases
112 pediatric patients with a median follow-up of 18 months were reviewed in an oral presentation at the 59th Annual Meeting of the American Society of Hematology 
From GlobeNewswire News Releases
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma
If you want a Stock Review on ARDX, BLCM, IOVA, or ITEK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, the NASDAQ Composite ended... 
From PR Newswire
Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair,... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.